We also reported that differential DNA methylation at estrogen-responsive enhancers is associated with endocrine response in breast cancer6, raising the possibility that dynamic three-dimensional (3D) chromatin remodelling of ER-mediated enhancer−promoter interactions could potentially underlie the development of endocrine resistance in breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.